Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study ; volume:26 ; number:1 ; day:21 ; month:12 ; year:2024 ; pages:1-10 ; date:12.2024
Arthritis Research & Therapy ; 26, Heft 1 (21.12.2024), 1-10, 12.2024
- Creator
-
Maharaj, Narendra
Uppada, Dharma Rao
Reddy, Naveen
Reddy, Pramod
Batalov, Anastas
lvanova, Delina
Staykova, Nedyalka
Baranauskaite, Asta
Hassan, Laila Amirali
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13075-024-03456-w
- URN
-
urn:nbn:de:101:1-2503022110239.691405045918
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Maharaj, Narendra
- Uppada, Dharma Rao
- Reddy, Naveen
- Reddy, Pramod
- Batalov, Anastas
- lvanova, Delina
- Staykova, Nedyalka
- Baranauskaite, Asta
- Hassan, Laila Amirali
- SpringerLink (Online service)
Other Objects (12)
Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab
Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar
Rituximab Biosimilar : Wissenswertes für Patientinnen, Patienten und ihre Angehörigen : deutsch
Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach
Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study
A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL)
Rituximab in Steroid-Dependent Podocytopathies
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
Rituximab : aktueller Stand der B-Zell-Therapie mit Rituximab bei Patienten mit rheumatoider Arthritis
The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
Rituximab for nephrotic syndrome in children
Rituximab therapy improves recalcitrant Pemphigus vulgaris
Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab
Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar
Rituximab Biosimilar : Wissenswertes für Patientinnen, Patienten und ihre Angehörigen : deutsch
Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach
Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study
A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL)
Rituximab in Steroid-Dependent Podocytopathies
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
Rituximab : aktueller Stand der B-Zell-Therapie mit Rituximab bei Patienten mit rheumatoider Arthritis
The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
Rituximab for nephrotic syndrome in children
Rituximab therapy improves recalcitrant Pemphigus vulgaris
Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab
Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar
Rituximab Biosimilar : Wissenswertes für Patientinnen, Patienten und ihre Angehörigen : deutsch
Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach
Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study
A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL)
Rituximab in Steroid-Dependent Podocytopathies
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma
Rituximab : aktueller Stand der B-Zell-Therapie mit Rituximab bei Patienten mit rheumatoider Arthritis
The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
Rituximab for nephrotic syndrome in children